<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00056238</url>
  </required_header>
  <id_info>
    <org_study_id>CL-758003</org_study_id>
    <nct_id>NCT00056238</nct_id>
  </id_info>
  <brief_title>Cerebril™ in Patients With Lobar Hemorrhage Related to Cerebral Amyloid Angiopathy</brief_title>
  <official_title>A Phase II Pilot Study of the Safety, Tolerability and Pharmacokinetics of Cerebril™ in Patients With Lobar Hemorrhage Related to Cerebral Amyloid Angiopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bellus Health Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Bellus Health Inc</source>
  <brief_summary>
    <textblock>
      The main objective of this study is to evaluate the safety, tolerability and pharmacokinetics&#xD;
      of Cerebril™ in Cerebral Amyloid Angiopathy (CAA) patients who have had lobar cerebral&#xD;
      hemorrhage.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hemorrhagic Stroke due to CAA represents approximately 7% of all strokes.&#xD;
&#xD;
      The current phase II clinical study investigates the safety, tolerability, pharmacokinetic&#xD;
      and pharmacodynamic profiles of the drug candidate in patients who have suffered lobar&#xD;
      hemorrhages. The initial phase of the study is also aimed at determining the optimal dosing&#xD;
      regimens for subsequent drug candidate efficacy trials. The trial is also evaluating the&#xD;
      appearance of new cerebral hemorrhages on gradient-echo MRI scans, the amyloid ß (Aß) protein&#xD;
      levels in the plasma and cerebrospinal fluid and the neurological and cognitive functions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2003</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>30</enrollment>
  <condition>Stroke</condition>
  <condition>Neurologic Diseases, General</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NC-758 (Anti amyloidotic [Aß] agent)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Patients must be 55 years of age or older.&#xD;
&#xD;
          -  Males and females. Females must be of non-childbearing potential (i.e. surgically&#xD;
             sterilized or at least one year post-menopausal).&#xD;
&#xD;
          -  Diagnosis of possible or probable CAA based on the Boston Criteria for Diagnosis of&#xD;
             CAA-Related Hemorrhage.&#xD;
&#xD;
          -  Nonfatal lobar hemorrhage (defined as hemorrhage in the cerebral cortex and underlying&#xD;
             white matter sparing the basal ganglia and thalamus) within previous five years&#xD;
             diagnosed by CT or MRI scan.&#xD;
&#xD;
          -  Patient has no intent to donate blood for 4 weeks after completion of the study.&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Other established causes of hemorrhage at the time of the index hemorrhage event.&#xD;
             Exclusion causes include excessive anticoagulation (INR &gt; 4.0), associated head trauma&#xD;
             or ischemic stroke, CNS tumor, vascular malformation, vasculitis, and blood dyscrasia.&#xD;
&#xD;
          -  Patient with a clinically significant and uncontrolled cardiovascular, renal, hepatic,&#xD;
             pulmonary, gastrointestinal, endocrine, metabolic, ophthalmologic, hematological&#xD;
             condition or other significant medical disease.&#xD;
&#xD;
          -  Presence of any condition that could interfere with the interpretation of study&#xD;
             results or compromise patient safety.&#xD;
&#xD;
          -  Debilitated neurological state or other known disease likely to result in early death.&#xD;
&#xD;
          -  Disability characterized by a modified Rankin score ≥ 4.&#xD;
&#xD;
          -  ALT, ALP, AST or total bilirubin ≥ 1.5 the upper limit of normal ranges.&#xD;
&#xD;
          -  Contraindications to MRI scan (e.g. cranial metallic implant, cardiac pacemaker, and&#xD;
             severe claustrophobia).&#xD;
&#xD;
          -  Allergy and/or hypersensitivity to analgesic agents used for the lumbar puncture (for&#xD;
             patients undergoing lumbar puncture only).&#xD;
&#xD;
          -  Allergy and/or hypersensitivity to any component of the study medication.&#xD;
&#xD;
          -  Use of an investigational drug within 30 days prior to Screening visit.&#xD;
&#xD;
          -  Use of warfarin or warfarin containing compounds and heparin or heparin containing&#xD;
             compounds within 7 days prior to Baseline (Week 0) visit.&#xD;
&#xD;
          -  Diagnosis of cystatin C amyloid angiopathy.&#xD;
&#xD;
          -  Active alcohol and/or drug abuse.&#xD;
&#xD;
          -  Inability to provide legal consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven M. Greenberg, M.D., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Co-sponsor: National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA</last_name>
  </overall_official>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gervais F, Chalifour R, Garceau D, Kong X, Laurin J, Mclaughlin R, Morissette C, Paquette J. Glycosaminoglycan mimetics: a therapeutic approach to cerebral amyloid angiopathy. Amyloid. 2001 Jul;8 Suppl 1:28-35.</citation>
    <PMID>11676287</PMID>
  </reference>
  <reference>
    <citation>M.C. Belanger, P. Krzywkowski, J. Paquette, M. Yu, C. Ramassamy, P. Tremblay, and F. Gervais. Development of Cerebral Amyloid Angiopathy in the TgCRND8 Mouse Model of Alzheimer's Disease. Data presented at the Society for Neuroscience, Orlando, FL, November 2002.</citation>
  </reference>
  <verification_date>March 2003</verification_date>
  <study_first_submitted>March 7, 2003</study_first_submitted>
  <study_first_submitted_qc>March 8, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2003</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Neurologic Diseases (General)</keyword>
  <keyword>Hemorrhagic Stroke</keyword>
  <keyword>Cerebral Amyloid Angiopathy</keyword>
  <keyword>Cerebrovascular Accident</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebral Amyloid Angiopathy</mesh_term>
    <mesh_term>Cerebral Amyloid Angiopathy, Familial</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

